公开(公告)号：US20240319174A1

公开(公告)日：2024-09-26

申请号：US18732216

申请日：2024-06-03

Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTER ,  SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH ,  MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES

Inventor： Karuna Ganesh

IPC: G01N33/50 ,  C12N1/20 ,  C12N5/0783 ,  C12N5/09 ,  C12Q1/02

CPC classification number: G01N33/5088 ,  C12N1/20 ,  C12N5/0636 ,  C12N5/0693 ,  C12Q1/025 ,  C12N2501/11 ,  C12N2501/415 ,  C12N2501/998 ,  C12N2503/02

Abstract: The present disclosure provides organoid co-cultures and methods of using such co-cultures. In particular, the present disclosure provides organoid-immune cell and organoid-bacterial cell co-cultures. The present disclosure further provides methods for testing therapeutic agents using the disclosed organoid co-cultures.

公开(公告)号：US12071648B2

公开(公告)日：2024-08-27

申请号：US16650492

申请日：2018-09-25

Applicant: GENOSKIN

Inventor： Claire Jardet ,  Pascal Descargues ,  Hanne Norsgaard ,  Paola Lovato

IPC: C12Q1/02 ,  C12N5/071

CPC classification number: C12Q1/025 ,  C12N5/0629 ,  C12N2501/15 ,  C12N2501/2301 ,  C12N2501/2302 ,  C12N2501/2323 ,  C12N2501/51 ,  C12N2501/515

Abstract: Disclosed is an ex-vivo model of inflamed skin, an in-vitro method for obtaining the same and uses thereof for screening anti-inflammatory compounds. The method includes injecting, into the dermis of a healthy skin biopsy previously taken from a mammal, a composition including an effective amount for activating dermal resident T cells of an anti-CD3 antibody and an anti-CD28 antibody; and b) incubating the injected skin biopsy obtained in step a) in the presence of a composition including an effective amount, for obtaining the polarization of the T cells activated in step a) into LTh1 and/or LTh17 and the synthesis of inflammation markers, of at least one mixture of IL-1β, IL-23, and TGF-β.

公开(公告)号：US20240254540A1

公开(公告)日：2024-08-01

申请号：US18433029

申请日：2024-02-05

Applicant: The University of Chicago ,  National Centre for Biological Sciences

Inventor： Yamuna Krishnan ,  Saheli Halder

IPC: C12Q1/6809 ,  C12N15/11 ,  C12N15/113 ,  C12Q1/00 ,  C12Q1/02 ,  C12Q1/6816 ,  C12Q1/6825 ,  C12Q1/6876 ,  G01N33/84

CPC classification number: C12Q1/6809 ,  C12N15/111 ,  C12N15/113 ,  C12Q1/005 ,  C12Q1/025 ,  C12Q1/6816 ,  C12Q1/6825 ,  C12Q1/6876 ,  G01N33/84 ,  C12N2310/14 ,  C12N2310/3517

Abstract: Described herein are nucleic acid molecules and complexes useful as i-switch pH reporters that have increased sensitivities as a pH reporter and have alternate pH reporting capacity ranges. Aspects of the disclosure relate to a method for determining pH comprising providing a nucleic acid complex comprising: a first single-stranded nucleic acid molecule comprising the sequence CnXCnYCnZCn (SEQ ID NO. 6) wherein C is cytosine; X, Y and Z are each one or more of adenine, thymine, guanine, or combinations thereof; and n is greater than or equal to 2; and wherein at least 2 cytosine residues of the first single-stranded nucleic acid molecule are modified; and a second single-stranded nucleic acid molecule that is partially or fully complementary to the first single-stranded molecule, wherein a first label is conjugated to the first single-stranded nucleic acid molecule or the second single-stranded nucleic acid molecule; and wherein the first label is capable of producing a signal, wherein the intensity of the signal varies as a function of the conformation of the nucleic acid complex; and measuring the intensity of the signal and determining the pH from the measured signal.

公开(公告)号：US11932846B2

公开(公告)日：2024-03-19

申请号：US16634898

申请日：2018-08-08

Applicant: Technology Innovation Momentum Fund (Israel) Limited Partnership

Inventor： Gali Prag

IPC: C12N15/10 ,  C12N15/03 ,  C12Q1/02 ,  C12Q1/48

CPC classification number: C12N15/1055 ,  C12N15/03 ,  C12Q1/025 ,  C12Q1/48 ,  C12Y203/01028 ,  G01N2333/91062 ,  G01N2500/02

Abstract: A system for expressing a chloramphenicol split protein is disclosed. Uses thereof are also disclosed.

公开(公告)号：US11926841B2

公开(公告)日：2024-03-12

申请号：US17481576

申请日：2021-09-22

Applicant: SIRION BIOTECH GmbH

Inventor： Ulrich Koszinowski ,  Simona Langer ,  Zsolt Ruzsics ,  Christian Thirion

IPC: C07H21/04 ,  C12N15/86 ,  C12Q1/02 ,  C12Q1/6897 ,  C12Q1/70

CPC classification number: C12N15/86 ,  C12Q1/025 ,  C12Q1/6897 ,  C12Q1/70 ,  C12N2750/14143 ,  C12N2750/14152 ,  C12N2830/002

Abstract: The present invention relates to a cell comprising (aa) a nucleic acid comprising in 5′ to 3′ direction (i) at least one adeno-associated virus (AAV) inverted terminal repeat (ITR) sequence; (ii) a promoter which is capable of being activated by (a) helper polypeptide(s) and optionally (a) helper polynucleotide(s); and (iii) a transgenic coding sequence under the control of said promoter of (aa)(ii); and (ab) a nucleic acid comprising in 5′ to 3′ direction (i) a promoter which is capable of being activated by said helper polypeptide(s) and optionally said helper polynucleotide(s); and (ii) at least one AAV rep gene coding sequence under the control of said promoter of (ab)(i); wherein said cell does not comprise an AAV cap gene and/or is not able to express any AAV cap gene product.

公开(公告)号：US11918702B2

公开(公告)日：2024-03-05

申请号：US16495557

申请日：2018-03-26

Applicant: The Trustees of Columbia University in the City of New York

Inventor： Hans-Willem Snoeck ,  Ya-Wen Chen

IPC: C12Q1/02 ,  A61L27/36 ,  A61L27/38 ,  A61L27/52 ,  C12N5/071 ,  G01N33/50

CPC classification number: A61L27/3633 ,  A61L27/3834 ,  A61L27/3882 ,  A61L27/3895 ,  A61L27/52 ,  C12N5/0689 ,  C12Q1/025 ,  G01N33/5082 ,  A61L2430/22 ,  C12N2501/117 ,  C12N2501/119 ,  C12N2501/385 ,  C12N2501/415 ,  C12N2503/04 ,  C12N2506/02 ,  C12N2506/45 ,  C12N2513/00 ,  C12N2533/90 ,  G01N2500/10

Abstract: Described herein are new methods for making lung bud organoids (LBOs) that have the capacity of developing into branching airways and alveolar structures that a least partially recapitulate human lung development from mammalian, preferably human, pluripotent stem cells including embryonic stem cells (ESCs) and induced pluripotent stem cells (IPSC), either by culturing branched LBO in a 3D matrix or by transplanting the LBO under the kidney capsule of immune deficient mice. Branched LBOs contain pulmonary endoderm and mesoderm compatible with pulmonary mesenchyme, and undergo branching morphogenesis. Also described are LBOs harboring certain mutations that induce a fibrotic phenotype, and methods of making same. The mutated (B)LBOs can be used for screening agents that may treat pulmonary fibrosis.

公开(公告)号：US11899014B2

公开(公告)日：2024-02-13

申请号：US16906669

申请日：2020-06-19

Applicant: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK

Inventor： Virginia Wood Cornish ,  Nili Ostrov ,  Miguel Jimenez ,  Sonja Billerbeck

IPC: G01N33/566 ,  C12Q1/02 ,  G01N33/74 ,  G01N33/50 ,  C12Q1/00 ,  C12Q1/06 ,  G01N33/569

CPC classification number: G01N33/566 ,  C12Q1/005 ,  C12Q1/02 ,  C12Q1/025 ,  C12Q1/06 ,  G01N33/5023 ,  G01N33/5038 ,  G01N33/569 ,  G01N33/5695 ,  G01N33/56911 ,  G01N33/56916 ,  G01N33/56961 ,  G01N33/74 ,  G01N2333/726

Abstract: The present invention provides sensor cells comprising a receptor that binds to an analyte indicative of the presence of an agent, where binding of the analyte to the receptor triggers a detection event that is indicative of the presence of the agent. In certain embodiments, the detection event is appearance of a reporter detectable by the naked eye. The present invention also provides uses of such sensor cells for detecting the presence of an agent in a sample.

公开(公告)号：US20240035063A1

公开(公告)日：2024-02-01

申请号：US18255344

申请日：2021-11-26

Applicant: Evonik Operations GmbH

Inventor： Tobias BLATTERT ,  Peter Lersch

IPC: C12Q1/02 ,  C12N1/20

CPC classification number: C12Q1/025 ,  C12N1/20 ,  G01N2500/10

Abstract: An in vitro method can be used for screening of the bioactivity of a compound by a synthetic mixed culture resembling a skin microbiome.

公开(公告)号：US11834697B2

公开(公告)日：2023-12-05

申请号：US16644539

申请日：2018-09-17

Applicant: OXFORD UNIVERSITY INNOVATION LIMITED

Inventor： Richard Guy Compton ,  Sabine Kuss

IPC: C12Q1/26 ,  C12Q1/02 ,  G01N27/327 ,  G01N27/416 ,  G01N27/48

CPC classification number: C12Q1/26 ,  C12Q1/025 ,  G01N27/3277 ,  G01N27/4161 ,  G01N27/48 ,  G01N2333/90216

Abstract: A method of determining the presence of bacteria expressing cytochrome c oxidase (‘the bacteria’), the method comprising: —providing a sample suspected of containing the bacteria; —providing a compound that has two redox states: a reduced state and an oxidised state, wherein cytochrome c oxidase can convert the compound from its reduced state to its oxidised state; —contacting an electrode either with (i) the compound in its oxidised state in the presence of the sample, then applying a reductive potential and measuring the current at the electrode; or (ii) the compound in its reduced state in the presence of the sample, then applying an oxidative potential and measuring the current at the electrode; and—comparing the magnitude of the current produced by the reductive potential or oxidative potential in the presence of the sample suspected of containing the bacteria with the magnitude of the current produced under the same conditions, but in the absence of the sample suspected of containing the bacteria, wherein a difference between the magnitude of current produced in the presence of the sample suspected of containing the bacteria and the magnitude of current produced in the absence of the sample suspected of containing the bacteria indicates the presence of the bacteria. Also provided herein is a sensor for determining the presence of bacteria expressing cytochrome c oxidase.

公开(公告)号：US20230295248A1

公开(公告)日：2023-09-21

申请号：US18153727

申请日：2023-01-12

Applicant: NEW YORK UNIVERSITY

Inventor： Victor J. TORRES ,  Ashley L. DUMONT

IPC: C07K14/31 ,  C07K16/12 ,  G01N33/50 ,  G01N33/569 ,  C12Q1/02 ,  G01N33/68

CPC classification number: C07K14/31 ,  C07K16/1271 ,  G01N33/5035 ,  G01N33/56938 ,  C12Q1/025 ,  G01N33/68 ,  A61K39/00

Abstract: Disclosed herein are isolated and purified Staphylococcus aureus bi-component leukocidin, referred to herein as LukAB, and its components LukA and LukB, antibodies specific to LukA, antibodies specific to LukB, therapeutic compositions containing LukA and/or LukB, or anti-LukA and/or anti-LukB antibodies, uses of the compositions to treat acute inflammatory conditions or S. aureus infection, methods for identifying inhibitors of LukAB-mediated cytotoxicity of human phagocytes, and methods for using LukAB as a marker to predict severity of S. aureus infection.